Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
16 mars 2023 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its...
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
02 mars 2023 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 02, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it...
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
24 janv. 2023 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific...
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
05 janv. 2023 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022,...
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
29 nov. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will...
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
28 nov. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
14 nov. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD
01 nov. 2022 08h00 HE
|
Galectin Therapeutics Inc.
Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertensionBiochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and...
Galectin Therapeutics to Present in Upcoming Conferences
14 oct. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
12 oct. 2022 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced that its Investigational...